Picture courtesy The News Minute
New Delhi: Ocugen Inc., Bharat Biotech’s partner for USA and Canada, has sought approval from the US Food and Drug Administration (FDA) for emergency use authorisation of Covaxin for paediatric use.
The submission is based on results of a Phase 2/3 paediatric clinical trial conducted by Bharat Biotech in India with 526 children 2-18 years of age, which bridged immunogenicity data to a large, Phase 3 safety and efficacy clinical trial in nearly 25,800 adults in India, Ocugen said in a regulatory filing, reported PTI.
“Filing for emergency use authorisation in the US for paediatric use is a significant step toward our hope to make our vaccine candidate available here and help combat the COVID-19 pandemic,” Shankar Musunuri, Chairman of the Board, Chief Executive Officer and Co-Founder of Ocugen said.
On November 3, the World Health Organisation gave emergency use licence to Covaxin. Travellers fully vaccinated with Covaxin can now enter the US from November 8, joining travellers fully vaccinated with other shots like Pfizer-BioNTech, Johnson & Johnson, Moderna, Oxford-AstraZeneca, Covishield, Sinopharm and Sinovac.
Mumbai: The first day of the IPL mega player auction at Jeddah threw up several…
Bhubaneswar: The Odisha government has handed over the investigation into the attack on Dhramasala MLA…
Bhubaneswar: The Commissionerate of Police on Sunday issued an advisory for movement of vehicular traffic…
New York: Now that President-elect Donald Trump has tasked Elon Musk with the responsibility of co-heading…
Bhubaneswar: The Odisha government has warned its employees of stern action for sub-letting their allotted…
Mumbai: There has been a lot of talk over AR Rahman and his wife Saira…
Sundargarh: The North Odisha Development Council (NODC) would be formed in 2-3 months, said Chief…
Puri: Director General of Police (DGP) YB Khurania on Sunday reviewed the security arrangements for…